Publications by authors named "Marco Russano"

Claim this Profile
L
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, Marco Russano

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.
Alessio Cortellini, Fabrizio Citarella, Alessia Vendittelli, Matteo Fiorenti, Emanuele Claudio Mingo, Marco Russano

J Chemother· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo, David J Pinato, Marco Russano

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study.
Alessandro Inno, Antonello Veccia, Ettore D'Argento, Floriana Morgillo, Elio Gregory Pizzutilo, Marco Russano

Cancer Immunol Immunother· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis.
Leonardo Brunetti, Valentina Santo, Alessandro Galletti, Alain Gelibter, Antonio Lugini, Marco Russano

Cancers (Basel)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group.
Chiara Catania, Claudia Proto, Chiara Bennati, Salvatore Grisanti, Ida Colantonio, Marco Russano

Crit Rev Oncol Hematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato, Marco Russano

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade.
Alessio Cortellini, Claudia Zampacorta, Michele De Tursi, Lucia R Grillo, Serena Ricciardi, Marco Russano

Pathologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).
Michele Iuliani, Sonia Simonetti, Leonardo Cristofani, Silvia Cavaliere, Alessio Cortellini, Marco Russano

J Immunother Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring Negated Entites for Named Entity Recognition in Italian Lung Cancer Clinical Reports.
Domenico Paolo, Alessandro Bria, Carlo Greco, Marco Russano, Sara Ramella

Stud Health Technol Inform· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
Arsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, Laura Mazzeo, Giuseppe Viscardi, Marco Russano

Clin Lung Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Giuseppe Lo Russo, Paolo Bironzo, Chiara Bennati, Laura Bonanno, Annamaria Catino, Marco Russano

Crit Rev Oncol Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Chiara Catania, Andrea Riccardo Filippi, Claudia Sangalli, Gaia Piperno, Marco Russano

Crit Rev Oncol Hematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Alessio Cortellini, Antonio D'Alessio, Siobhan Cleary, Sebastiano Buti, Melissa Bersanelli, Marco Russano

Clin Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Management of the patient with extensive stage microcytoma. The importance of collaboration between oncology and radiotherapy.].
Gabriele Minuti, Alessio Stefani, Luca Trodella, Giancarlo Antonini Cappellini, Fabiana Cecere, Marco Russano

Recenti Prog Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.
Marco Russano, Giulia La Cava, Alessio Cortellini, Fabrizio Citarella, Alessandro Galletti

Curr Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Antonio Passaro, Giuseppe Lo Russo, Francesco Passiglia, Manolo D'Arcangelo, Andrea Sbrana, Marco Russano

Lung Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients.
Francesco Pantano, Francesca Zalfa, Michele Iuliani, Sonia Simonetti, Paolo Manca, Marco Russano

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.
Roberto Filippi, Francesco Leone, Lorenzo Fornaro, Giuseppe Aprile, Andrea Casadei-Gardini, Marco Russano

J Chemother· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Marco Russano, Alessio Cortellini, Raffaele Giusti, Alessandro Russo, Federica Zoratto

Cancer Immunol Immunother· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
Alessio Cortellini, Raffaele Giusti, Marco Filetti, Fabrizio Citarella, Vincenzo Adamo, Marco Russano

J Hematol Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.].
Gabriele Minuti, Alessio Stefani, Silvia Carpano, Ettore D'Argento, Raffaele Giusti, Marco Russano

Recenti Prog Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the role of respiratory microbiome in lung cancer: A systematic review.
Fabiana Perrone, Lorenzo Belluomini, Marco Mazzotta, Maristella Bianconi, Vincenzo Di Noia, Marco Russano

Crit Rev Oncol Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations.
Fabrizio Citarella, Marco Russano, Giuseppe Perrone, Bruno Vincenzi, Giuseppe Tonini

Thorac Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
Daniele Santini, Tea Zeppola, Marco Russano, Fabrizio Citarella, Cecilia Anesi

J Transl Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis